SynthesisArthritis & rheumatology (Hoboken, N.J.)2020
Effect of Therapy on Radiographic Progression in Axial Spondyloarthritis: A Systematic Review and Meta-Analysis.
Synthesis in Arthritis & rheumatology (Hoboken, N.J.), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 2 syntheses or guidelines pooled it, 68 citations in OpenAlex.
- Exercise prescription for axial spondyloarthritis: a systematic review and meta-analysis of randomized controlled trials.Frontiers in medicine · 2026Pooled it
- Pooled it
- Patient Diagnostic Journey and Time to Diagnosis in Axial Spondyloarthritis: A Retrospective Cohort Study Using US Claims Data.Rheumatology and therapy · 2025Article
- The 2025 British Society for Rheumatology guideline for the treatment of axial spondyloarthritis with biologic and targeted synthetic DMARDs.Rheumatology (Oxford, England) · 2025Article
- Osteoclast development from peripheral blood monocytes is reduced in patients with radiographic axial spondyloarthritis on biological therapy.Arthritis research & therapy · 2025Article
- IL-33-Induced TREM2Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Disparities in Time to Diagnosis of Radiographic Axial Spondyloarthritis.The Journal of rheumatology · 2025Observational
- State-of-the-Art Review on the Treatment of Axial Spondyloarthritis.Medical sciences (Basel, Switzerland) · 2025Review
- The Spondyloarthritides: From Scientific and Therapeutic Immobility to the Forefront of Rheumatology Research.Mediterranean journal of rheumatology · 2024Article
- Characteristics and burden of disease in patients with radiographic versus non-radiographic axial spondyloarthritis in the ASRI cohort.Irish journal of medical science · 2024Article
- Rationale and concerns for using JAK inhibitors in axial spondyloarthritis.Rheumatology advances in practice · 2024Review
- Trends in Fracture Rates Over Two Decades Among Veterans With Ankylosing Spondylitis.Arthritis care & research · 2023Article
- Angiotensin receptor blockers, but not angiotensin-converting enzyme inhibitors, inhibit abnormal bone changes in spondyloarthritis.Experimental & molecular medicine · 2023Article
- Biomechanics in the onset and severity of spondyloarthritis: a force to be reckoned with.RMD open · 2023Review
- Updates on ankylosing spondylitis: pathogenesis and therapeutic agents.Journal of rheumatic diseases · 2023Review
- Management of Specific Clinical Profiles in Axial Spondyloarthritis: An Expert's Document Based on a Systematic Literature Review and Extended Delphi Process.Rheumatology and therapy · 2023Article
- Quantitative prediction of radiographic progression in patients with axial spondyloarthritis using neural network model in a real-world setting.Arthritis research & therapy · 2023Article
- Uncovering the Underworld of Axial Spondyloarthritis.International journal of molecular sciences · 2023Review
- [Chronic back pain in axial spondylarthritis : Current diagnostic challenges and treatment possibilities].Zeitschrift fur Rheumatologie · 2023Review
- Identifying trajectories of radiographic spinal disease in ankylosing spondylitis: a 15-year follow-up study of the PSOAS cohort.Rheumatology (Oxford, England) · 2022Observational
Corrections and comments
- Commented on by
- Commented on byReply.2020
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
Abstract
objectiveTo investigate the effect of therapies on radiographic progression in patients with axial spondyloarthritis (SpA).
methodsA comprehensive database search for studies assessing radiographic progression in axial SpA (particular treatment versus no treatment of interest) was performed. Study-specific standardized mean differences in treatment outcomes at 2 and ≥4 years were estimated and combined using random-effects models.
resultsTwenty-four studies in patients with axial SpA were identified, of which 18 involved tumor necrosis factor inhibitors (TNFi), 8 involved nonsteroidal antiinflammatory drugs (NSAIDs), and 1 involved secukinumab. Spinal radiographic progression, as measured by the modified Stoke Ankylosing Spondylitis Spine Score (mSASSS), was not significantly different between TNFi-treated and biologics-naive patients at 2 years (mSASSS difference -0.73 [95% confidence interval (95% CI) -1.52, 0.12], I
conclusionAlthough no significant protective effect of TNFi treatment on spinal radiographic progression was seen over the course of 2 years or ≥4 years in patients with axial SpA, our analysis restricted to studies with a low risk of bias showed a protective effect of TNFi after ≥4 years. Therefore, long-term TNFi exposure might confer beneficial effects on spinal radiographic progression in axial SpA. No difference in radiographic progression at 2 years was seen in either the NSAID or secukinumab treatment groups compared to their controls. Future studies should explore the effects of biologic treatment on radiographic progression, as well as the effects of long-term biologics exposure, in patients with early axial SpA or those with nonradiographic axial SpA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.